NCT06295965Recruiting
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
University of Washington
Start Date
1/2/2024
Completion Date
12/31/2031
Summary
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
Detailed Description
OUTLINE: This is an observational study. Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.
Eligibility Criteria
Age Range: No minimum to No maximum
Inclusion Criteria:
* Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
* Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
OR
* Subjects who have or have had a solid tumor diagnosis and any of the following:
* At least 4 months of exposure to a PARP inhibitor
* Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm
Exclusion Criteria:
* Individuals with a life expectancy of less than 6 months
Interventions
OTHER
Non-Interventional Study
Conditions
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Malignant Solid NeoplasmClonal Cytopenia of Undetermined SignificanceClonal HematopoiesisIdiopathic Cytopenia of Undetermined SignificanceNon-Neoplastic Hematopoietic and Lymphoid Cell DisorderOvarian CarcinomaMyeloid Neoplasm Post Cytotoxic Therapy
Locations
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington 98109
United States